Patented Medicine Prices Review Board's multi-stakeholder Steering Committee holds first meeting
As previously reported ( here and here), the Patented Medicine Prices Review Board (PMPRB) has been consulting on its proposed reform of the federal price review process and associated guidelines. As part of this reform, the Steering Committee (Committee) held its first meeting on June 25, 2018, "to discuss aspects of the new regime and assist the PMPRB in synthesizing stakeholder views on key technical and operational modalities of new draft Guidelines that would give effect to these changes." According to the Presentation to Steering Committee, the Committee had "until July 13 to identify further issues it believes would benefit from expert review and analysis." Additional reference materials from the Committee's meeting can be found here (with meeting minutes still to come).
PMPRB releases annual report on drug market entry
On June 26, 2018, the PMPRB announced the publication of the second annual edition of Meds Entry Watch, 2016. The report provides a review of long-term trends in new active substances approved by the U.S. Food and Drug Administration, the European Medicines Agency and/or Health Canada during the period 2009-2015, describes, among other things, their availability, pricing and sales in 2015-2016, and provides a preliminary analysis of their effect on the market as of Q4-2016.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
